Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price was up 6.1% during trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as $5.07 and last traded at $5.07, with a volume of 117,289 shares trading hands. The stock had previously closed at $4.78.

Specifically, major shareholder International S. Pharmstandard bought 5,580 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was purchased at an average cost of $4.76 per share, for a total transaction of $26,560.80. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder International S. Pharmstandard bought 41,259 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The shares were bought at an average price of $4.77 per share, with a total value of $196,805.43. The disclosure for this purchase can be found here. 61.64% of the stock is currently owned by company insiders.

Several equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, August 15th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research note on Friday, June 17th. FBR & Co cut their target price on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 11th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research note on Monday, June 20th. Eight analysts have rated the stock with a buy rating, Argos Therapeutics has an average rating of “Buy” and an average price target of $11.50.

The firm’s market cap is $203.51 million. The stock’s 50 day moving average is $4.80 and its 200 day moving average is $5.95.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. On average, equities research analysts forecast that Argos Therapeutics Inc. will post ($1.55) earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in ARGS. BlackRock Fund Advisors boosted its position in Argos Therapeutics by 880.1% in the second quarter. BlackRock Fund Advisors now owns 281,679 shares of the biopharmaceutical company’s stock valued at $1,727,000 after buying an additional 252,940 shares in the last quarter. Sanders Morris Harris Inc. purchased a new position in Argos Therapeutics during the first quarter valued at $907,000. Vanguard Group Inc. boosted its position in Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock valued at $2,314,000 after buying an additional 137,390 shares in the last quarter. State Street Corp purchased a new position in Argos Therapeutics during the second quarter valued at $741,000. Finally, BlackRock Institutional Trust Company N.A. purchased a new position in Argos Therapeutics during the second quarter valued at $363,000. 11.05% of the stock is owned by institutional investors and hedge funds.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.